STUDIES OF IMMUNOLOGICALLY RELEVANT CELL SURFACE PHENOMENA

1.克隆的人细胞毒性细胞（CTL）已经通过使用 含有与抗-靶交联的抗-T3的抗体异源聚集体 细胞抗体 我们已经证明，通过使用这种技术克隆CTL， 失去了它们正常的特异性，可以溶解同种异体的， 异种肿瘤细胞，甚至鸡红细胞。 这些结果 表明效应细胞阻滞可用于体内治疗 表达独特表面抗原的肿瘤和其他病原体。 2.为了获得可能用于体内施加的效应细胞， 肿瘤和其他致病细胞的细胞介导死亡，人外周血 血液白细胞已经用含有抗T3的抗体处理 并测试了裂解肿瘤细胞表达的能力。 由所述异源聚集体的第二抗体识别的抗原。 人类 当以这种方式处理时，外周血T细胞是有效和特异的 靶细胞裂解的介质。 这是真的，没有事先激活，但 短暂暴露于重组IL-2迅速增加细胞溶解活性 提升到更高的水平 在这种情况下，效应细胞是T8+。

1. Cloned human cytotoxic cells (CTL) have been retargeted by using antibody heteroaggregates containing anti-T3 cross linked to anti-target cell antibodies. We have shown that by using this technique cloned CTL lose their normal specificity and can be made to lyse allogeneic and xenogeneic tumor cells, and even chicken red blood cells. These results suggest that effector cell retargetting could be used in vivo to treat neoplasms and other pathogens which express distinctive surface antigens. 2. In order to obtain effector cells which might be used in vivo to inflict cell mediated death upon tumor and other pathogenic cells, human peripheral blood leukocytes have been treated with anti-T3 containing antibody heteroaggregates and tested for the ability to lyse tumor cells expressing an antigen recognized by the second antibody of the heteroaggregate. Human peripheral blood T-cells when treated in this way are potent and specific mediators of target cell lysis. This is true without prior activation, but brief exposure to recombinant IL-2 rapidly increases the cytolytic activity to an even higher level. The effector cells in this case are T8+.